‡Pain intensity of the target PN was self-reported by patients ≥8 years of age using the NRS-11.3
- NF1 with symptomatic, inoperable PN (defined as PN that could not be completely surgically removed without risk of substantial morbidity due to PN location, invasiveness, or high vascularity)
- At least 1 clinically significant PN-related morbidity
- Evidence of MPNST, an optic glioma, malignant glioma, or other cancers requiring treatment with chemotherapy or radiation therapy
- 42% (21/50) of patients had a progressive PN (growth ≥20% within 15 months prior to enrollment)
- 30% (15/50) of patients had a non-progressive PN at baseline
- Median target PN volume was 487 mL (range: 5 mL to 3820 mL)
- 24% (12/50) of patients had target PN in the neck and trunk
- 24% (12/50) of patients had target PN in the trunk and limbs
- Other patients had PN residing in the limbs, head, trunk only, or the head and neck
- Patients had a median of 3 (range: 1 to 5) PN-related complications
- The most common morbidities (≥20% of patients) were3: disfigurement (44/50; 88%), motor dysfunction (33/50; 66%), pain (26/50; 52%), airway dysfunction (16/50; 32%), visual impairment (10/50; 20%), and bladder/bowel dysfunction (10/50; 20%)
#The ORR assessment was conducted by a single NCI reviewer who was a SPRINT investigator and who evaluated all PN imaging from patients enrolled at all trial sites.1
||One more patient achieved ≥20% tumor shrinkage after 1.6 years.1,5
‡‡95% CI: 41.2, NE.
§§A cycle was defined as 28 days.
¶¶At DCO June 2018, the median time to onset of response was 7.2 months (range: 3.3 months to 1.6 years).
Additionally, due to variability in tumor size, location, and relation to pain and other symptoms, statistical analyses failed to establish a direct correlation between tumor size reduction and patient-reported results.
Therefore, these findings should be interpreted with caution.
After 12 months of treatment, a change of −≥2 points from baseline was observed in 74% (14/19) of patients 8 to 18 years of age with a baseline NRS-11 score of >0.3†††
***NRS-11 is a self-report that assesses the pain intensity of the physician-selected target tumor on an 11-point numeric scale over the past week.3,4
†††Physician-selected target tumor.3
‡‡‡The Pain Interference Index is a 6-item measure that assesses the degree to which pain has interfered with daily activities in the past week.3,4
Stridor (noisy breathing)
History of URIs, likely secondary to airway deviation
Frequent need for oral steroids
Café-au-lait macules and axillary freckling, suggestive of NF1
Prominence on the right cheek and left neck, suggestive of NF1
PN extending from right mandible to the left brachial plexus/left upper extremity and left lung
Individual results may vary. Patient images courtesy of D Van Mater, MD.
OneSource is Alexion’s free, personalized patient support program that ensures continuity of care and access to Koselugo from childhood to adulthood.
- Navigating health insurance coverage
- Ensuring continuous access to Koselugo
- Providing personalized disease and treatment education
- Hosting events to connect the NF1 PN community
- Providing educational resources
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Left Ventricular Dysfunction. Koselugo can cause cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF) ≥10% below baseline. In the pediatric safety pool, Grade 2 LVEF decrease occurred, as well as decreased LVEF of ≥20% resulting in dose interruption and dose reduction. The median time to first occurrence of LVEF decrease was approximately 12 months. In the adult population, Grade 2 LVEF decrease occurred, with decreased LVEF resulting in dose interruption. The median time to first occurrence of LVEF decrease was approximately 4 months. Assess ejection fraction by echocardiogram prior to initiating treatment, every 3 months during the first year of treatment, every 6 months thereafter, and as clinically indicated. Withhold, reduce dose, or permanently discontinue Koselugo based on severity of adverse reaction. In patients who interrupt Koselugo for decreased LVEF, obtain an echocardiogram or a cardiac MRI every 3 to 6 weeks until resolution. Upon resolution of decreased LVEF, obtain an echocardiogram or a cardiac MRI every 2 to 3 months.
Ocular Toxicity. Koselugo can cause ocular toxicity, including retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), and blurred vision. In the pediatric safety pool, blurred vision, photophobia, cataracts, ocular hypertension, and retinal tear occurred. Blurred vision resulted in dose interruption. RPED occurred in the pediatric population during treatment with Koselugo and resulted in permanent discontinuation. In the adult population, blurred vision and vitreous floaters occurred in patients receiving Koselugo. Conduct ophthalmic assessments prior to initiating Koselugo, at regular intervals during treatment, and for new or worsening visual changes. Permanently discontinue Koselugo in patients with RVO. Withhold Koselugo in patients with RPED, conduct ophthalmic assessments every 3 weeks until resolution, and resume Koselugo at a reduced dose.
Gastrointestinal Toxicity. Koselugo can cause gastrointestinal toxicities, including diarrhea and colitis. In the pediatric safety pool (N=134), diarrhea occurred in 59% of patients, in addition to diarrhea resulting in permanent discontinuation and dose interruption. In the adult population (N=71), diarrhea occurred in 42% of patients who received Koselugo, in addition to diarrhea resulting in dose interruption. The median time to first onset of diarrhea was approximately 2 months in the pediatric safety pool and 1 month in the adult population. Advise patients to start an anti-diarrheal agent (eg, loperamide) and to increase fluid intake immediately after the first episode of diarrhea. Withhold, reduce dose, or permanently discontinue Koselugo based on severity of adverse reaction.
Skin Toxicity. Koselugo can cause severe rashes, including dermatitis acneiform. In the pediatric safety pool (N=134), rash occurred in 68% of patients. The most frequent rashes included dermatitis acneiform (47%) and maculopapular rash (31%). Pruritus, alopecia, and eczema occurred. In the adult population (N=71), rash occurred in 85% of patients who received Koselugo. The most frequent rash included dermatitis acneiform (66%). Alopecia and pruritus occurred in patients who received Koselugo. Grade 3 rash and rash resulting in dose interruption and dose reduction occurred in both the pediatric safety pool and the adult population. Permanent discontinuation also occurred in the adult population. Monitor for severe skin rashes. Withhold, reduce dose, or permanently discontinue Koselugo based on severity of adverse reaction.
Increased Creatine Phosphokinase (CPK). Koselugo can cause increased CPK, myalgia, and rhabdomyolysis. In the pediatric safety pool (N=134), increased CPK, based on laboratory data, occurred in 73% of patients, including Grade 3 or 4. In the adult population (N=71), increased CPK, based on laboratory data, occurred in 70% of patients who received Koselugo, including Grade 3 or 4. Increased CPK resulted in dose interruption and dose reduction in both the pediatric safety pool and adult population. Increased CPK concurrent with myalgia occurred in both populations, including one patient who permanently discontinued Koselugo for myalgia in the pediatric safety pool. Obtain serum CPK prior to initiating Koselugo, periodically during treatment, and as clinically indicated. If increased CPK occurs, evaluate for rhabdomyolysis or other causes. Withhold, reduce dose, or permanently discontinue Koselugo based on severity of adverse reaction.
Increased Levels of Vitamin E and Risk of Bleeding (Koselugo Capsules). Koselugo capsules contain vitamin E, which can inhibit platelet aggregation and antagonize vitamin K-dependent clotting factors. Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in Koselugo and supplement) will exceed the recommended or safe limits due to increased risk of bleeding. An increased risk of bleeding may occur in patients who are co-administered vitamin-K antagonists or anti-platelet antagonists with Koselugo capsules. Monitor for bleeding in these patients and increase international normalized ratio (INR) monitoring in patients taking a vitamin-K antagonist. Perform anticoagulant assessments more frequently and adjust the dose of vitamin-K antagonists or anti-platelet agents as appropriate. Koselugo oral granules do not contain vitamin E.
Embryo-Fetal Toxicity. Koselugo can cause fetal harm when administered during pregnancy. In animal studies, administration of selumetinib to mice during organogenesis caused reduced fetal weight, adverse structural defects, and effects on embryo-fetal survival at approximate exposures >5 times the human exposure at the clinical dose of 25 mg/m2 twice daily. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Koselugo and for 1 week after the last dose.
ADVERSE REACTIONS
Common adverse reactions ≥40% in pediatric patients include vomiting, diarrhea, increased CPK, dry skin, paronychia, nausea, dermatitis acneiform, and pyrexia.
Common adverse reactions ≥40% in adult patients include rash (all), dermatitis acneiform, and diarrhea.
DRUG INTERACTIONS
Effect of Other Drugs on Koselugo
Concomitant use of Koselugo with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations, which may increase the risk of adverse reactions. Avoid coadministration with Koselugo. If coadministration cannot be avoided, reduce Koselugo dosage.
Concomitant use of Koselugo with a strong or moderate CYP3A4 inducer decreased selumetinib plasma concentrations, which may reduce Koselugo efficacy. Avoid concomitant use with Koselugo.
SPECIAL POPULATIONS
Pregnancy & Lactation. Verify the pregnancy status of patients of reproductive potential prior to initiating Koselugo. Due to the potential for adverse reactions in a breastfed child, advise patients not to breastfeed during treatment with Koselugo and for 1 week after the last dose.
To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or at https://us-aereporting.astrazeneca.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
INDICATIONKOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Please see full Prescribing Information for Koselugo (selumetinib) at https://alexion.com/Documents/koselugo_uspi.pdf.